Frequently Relapsing Minimal Change Disease: Rituximab or a Calcineurin Inhibitor
A single patient in his fourth relapse of minimal change disease, three of them inside two years, with real accumulated steroid toxicity. The disagreement is which steroid-sparing agent actually buys him treatment-free years, not just another remission.
Anthony B. was diagnosed with minimal change disease at thirty-two after a summer of unexplained ankle swelling that his doctor at the time assumed was a heart problem until the urine protein came back nephrotic-range. Nine years on, in his fourth relapse and his third inside the last two years, he has learned to recognize the swelling himself before it shows up on a lab slip, but he's also developed the accumulated cost of nine years of intermittent high-dose prednisone: bilateral posterior subcapsular cataracts that will eventually need surgery, eighteen kilograms of weight gain he's never fully lost between courses, and a DEXA scan last year that came back with a T-score of -1.6 — osteopenia, not osteoporosis, but arrived at by forty-one rather than by sixty-five, which is the part that matters for how many more courses he can absorb. He told his nephrologist directly, without being asked, that he wants to talk seriously about not doing another steroid course the same way.
Adult minimal change disease has never had the randomized-trial depth that pediatric relapsing nephrotic syndrome has, so the steroid-sparing decision here leans more on extrapolated case-series evidence than a single definitive trial — an honest limitation worth naming rather than glossing over. Calcineurin inhibitors have the longer track record, effective as steroid-sparing therapy in adult MCD and FSGS going back decades, though tacrolimus brings its own real costs: nephrotoxicity in a kidney that's otherwise healthy, tremor, new-onset hyperglycemia, years of drug-level monitoring. Rituximab's case rests on a narrower but more targeted body of evidence — Ruggenenti's cohort of steroid-dependent, frequently relapsing adults achieved durable remission off both steroids and calcineurin inhibitors in a meaningful share of patients, which is a genuinely different kind of outcome than trading one chronic drug exposure for another. For a man who has already told the room he wants to minimize further drug burden, not just switch which drug he's burdened by, that distinction is the actual crux. His DEXA T-score of -1.6 is worth reading rather than filing away as background: osteopenia at forty-one is not the same finding as osteopenia at sixty-five, because it leaves four more decades for the deficit to compound, and at his current pace — three relapses in two years — the next decade would plausibly finish what nine years have already started. That acceleration, more than the cumulative total, is why the room is treating this relapse differently than his first three.
In clinic, after the fourth relapse
Tacrolimus has the longest track record we have for steroid-sparing therapy in adult nephrotic syndrome. It's predictable, we know how to monitor it, and it works. I understand he wants off steroids — tacrolimus does that reliably, even if it means trading one chronic drug for another.
I'd push back on 'trading one chronic drug for another' as the right frame here. Ruggenenti's cohort — steroid-dependent, frequently relapsing adults, close to his exact profile — found durable remission off BOTH steroids and calcineurin inhibitors in a real share of patients after rituximab. That's not a substitution, that's the treatment-free outcome he's actually asking for.
Tacrolimus solves the steroid problem by creating a new chronic-exposure problem in its place — he told us directly he wants less drug burden overall, not a different drug indefinitely.
I want to name something both of you are working around: adult MCD doesn't have the randomized-trial depth pediatric relapsing nephrotic syndrome does. Neither tacrolimus nor rituximab rests on a definitive trial here — both extrapolate from cohort and case-series evidence, honestly.
That said, I think the rituximab argument is the stronger fit for what he's actually asked for. Mycophenolate is the lower-risk option on paper, but it doesn't offer the treatment-free possibility Ruggenenti's data describes, and he's been explicit that ongoing drug exposure — of any kind — is exactly what he's trying to get away from. I'd defer to rituximab here, not because mycophenolate is wrong in general, but because it doesn't answer his actual stated goal.
Agreed: rituximab, two doses, with prednisone tapered over the following 8 weeks as rituximab's effect establishes. Proteinuria and CD19 B-cell counts monitored at 3 and 6 months.
The tacrolimus and mycophenolate positions weren't dismissed as wrong — both nephrologists agreed either would be reasonable if rituximab failed to produce a durable response, and that fallback sequence was set explicitly rather than left as an open question for a future relapse.